Learn More
BACKGROUND The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasibility(More)
Fabrice Barlesi, Helene Blons, Michele Beau-Faller, Isabelle Rouquette, L’houcine Ouafik, Jean Mosser, Jean-Philippe Merlio, Pierre Paul Bringuier, Philippe Jonveaux, Cedric Le Marechal, Marc G.(More)
We assessed the prognostic and predictive value of β-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage(More)
BACKGROUND The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC). To determine whether drug intensification improves survival of(More)
BACKGROUND MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In a(More)